# JeNaCell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jenacell

- Industry: Biotechnology
- Headquarters: Jena, Germany
- Website: www.jenacell.com
- Total disclosed funding: $0.9M
- Latest round: Series A (Jul 12, 2015)
- Investors on record: 5

## About

Based in Thüringen, Germany, and co-founded by Dana Kralisch (CEO) in 2012, as a spin-off from the Friedrich Schiller University of Jena in Germany, JeNaCell GmbH operates as a biotechnology company specializing in bio-material with natural nanostructures. In August 2021, the firm was acquired by Evonik Industries AG from High-Tech Gründerfonds, STIFT, bm-t beteiligungsmanagement Thüringen, and Sparkasse Jena.

The company develops and produces products using biosynthetic cellulose, a nature-inspired material with bioengineered architecture generated by bacteria, to support customers in medical devices, wound care, and advanced dermatology. JeNaCell's product portfolio includes brands like BIOCELLIC®, a soft, flexible, moist, and cool base material, produced from sugar using a biotechnological fermentation process for custom developments, EPI NOUVELLE®, a skin-friendly biomaterial made from vegetable raw materials, and EPICITE® BALANCE, a wound dressing for the treatment of chronic and slow healing wounds.

## Funding rounds

- Series A, Jul 12, 2015 — Evonik Industries AG, High-Tech Gruenderfonds, Bm-t, Sparkasse Jena, STIFT
- Seed, Sep 14, 2012, $0.9M — High-Tech Gruenderfonds, STIFT

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series A
- STIFT — Seed, Series A
- Evonik Industries AG — Series A
- Bm-t (https://capitalatlas.ai/funds/bm-t) — Series A
- Sparkasse Jena — Series A